original article
Annals of Oncology 17: 1134–1140, 2006
doi:10.1093/annonc/mdl086
Published online 28 April 2006
Allogeneic haematopoietic stem cell transplantation for
metastatic renal carcinoma in Europe
L. Barkholt1*, M. Bregni2, M. Remberger1, D. Blaise3, J. Peccatori2, G. Massenkeil4,
P. Pedrazzoli5, A. Zambelli6, J.-O. Bay7, S. Francois8, R. Martino9, C. Bengala10, M. Brune11,
S. Lenhoff12, A. Porcellini13, M. Falda14, S. Siena5, T. Demirer15, D. Niederwieser16 & O. Ringdén1
On behalf of the French ITAC group and the EBMT Solid Tumour Working Party
Received 11 January 2006; revised 10 March 2006; accepted 17 March 2006
original
article
Background: An allogeneic antitumour effect has been reported for various cancers. We evaluated the experience
of allogeneic haematopoietic stem cell transplantation (HSCT) for renal cell carcinoma (RCC) in 124 patients from
21 European centres.
Patients and methods: Reduced intensity conditioning and peripheral blood stem cells from an HLA-identical
sibling (n = 106), a mismatched related (n = 5), or an unrelated (n = 13) donor were used. Immunosuppression was
cyclosporine alone, or combined with methotrexate or mycophenolate mofetil. Donor lymphocyte infusions (DLI) were
given to 42 patients. The median follow-up was 15 (range 3–41) months.
Results: All but three patients engrafted. The cumulative incidence of moderate to severe, grades II–IV acute GVHD
was 40% and for chronic GVHD it was 33%. Transplant-related mortality was 16% at one year. Complete (n = 4) or
partial (n = 24) responses, median 150 (range 42–600) days post-transplant, were associated with time from diagnosis to
HSCT, mismatched donor and acute GVHD II-IV. Factors associated with survival included chronic GVHD (hazards
ratio, HR 4.12, P < 0.001), DLI (HR 3.39, P < 0.001), <3 metastatic sites (HR 2.61, P = 0.002) and a Karnofsky
score >70 (HR 2.33, P = 0.03). Patients (n = 17) with chronic GVHD and given DLI had a 2-year survival of 70%.
Conclusion: Patients with metastatic RCC, less than three metastatic locations and a Karnofsky score >70% can be
considered for HSCT. Posttransplant DLI and limited chronic GVHD improved the patient survival.
Key words: allogeneic stem cell transplantation, antitumour effect, reduced intensity conditioning,
renal cell carcinoma
introduction
The fact that the immune system may control cancer is evident
by both experimental and clinical studies [1–4]. In clinical
allogeneic haematopoietic stem cell transplantation (HSCT),
graft-versus-host disease (GVHD) was found to contribute to an
antileukaemic effect. Such an antileukaemic effect is most
probably induced by donor T-lymphocytes and is seen both for
the acute and the chronic form of GVHD. The graft-versusleukaemia effect may be induced or enhanced by post-transplant
addition of donor lymphocyte infusions (DLI) [5]. The effect of
*Correspondence to: Dr L. Barkholt, Associate Professor, Centre for Allogeneic Stem
Cell Transplantation, Karolinska University Hospital Huddinge, Karolinska Institutet,
SE-141 86 Stockholm, Sweden. Tel: +46 8 585 80000;
Fax: +46 8 585 87870; E-mail: lisbeth.barkholt@karolinska.se
ª 2006 European Society for Medical Oncology
DLI has been especially pronounced in patients with chronic
myeloid leukaemia (CML). An allogeneic graft-versus-tumour
(GVT) effect has also been reported for breast cancer, renal cell
carcinoma (RCC), colon carcinoma and ovarian carcinoma
[6–13]. Although responses have been reported in some
patients, many patients have died of progressive disease [8–16].
Childs and co-workers reported responses in 10 out of 19
patients who underwent HSCT for RCC, which was associated
with acute GVHD with no apparent effect of DLI [9]. Because
of the variability in the outcome, there has been uncertainty
regarding the indications for HSCT in RCC. Furthermore,
which patients should be selected and what is the optimal
protocol? We here report the European experience in 124
patients who underwent HSCT for RCC. Since metastatic RCC
is resistant to chemoradiotherapy, all patients were treated
Downloaded from http://annonc.oxfordjournals.org/ by guest on August 29, 2015
1
Division of Clinical Immunology and Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden; 2Istituto Scientifico
H.S. Raffaele, Milan, Italy; 3Institut Paoli Calmettes, Marseille, France; 4Hospital Charité, Berlin, Germany; 5Ospedale Niguarda Ca’ Granda, Milan, Italy; 6Fondazione S.
Maugeri, Pavia, Italy; 7Centre Jean Perrin-CHU, Clermont Ferrand, France; 8CHRU Angers, France; 9Hospital Santa Creu I Sant Pau, Barcelona, Spain; 10St. Chiara
University Hospital, Pisa, Italy; 11Sahlgrenska University Hospital, Gothenburg, Sweden; 12Lund University Hospital, Lund, Sweden; 13Departimento di Oncologia/
Ematologia, Ospedale P.F. Calvi Noale, Italy; 14Azienda Ospedaliera S. Giovanni, Torino, Italy; 15Ankara University Medical School, Ankara, Turkey; 16University Hospital
Leipzig, Leipzig, Germany
original article
Annals of Oncology
with reduced intensity conditioning (RIC) to induce marked
immunosuppression and pave the way for the donor
immunohaematopoietic system [17–19]. Based on analyses of
two European prospective studies, we suggest which patients are
more likely to have an immune mediated response, and which
parameters are associated with tumour response and survival.
patients and methods
preparative regimens
2
Mainly four RIC regimens were used: (1) fludarabine (FLU, 125 mg/m ) and
cyclophosphamide (CY, 120 mg/kg) in 53 patients, (2) thiotepa (5–10 mg/
kg/day) for 2 days, FLU 30 mg/m2 days –4 and –3 in one patient and
combined with CY 30 mg/kg days –4 and –3 in 29 patients, (3) FLU 125 mg/
m2, busulphan (8 mg/kg) and anti-T-cell globulin (ATG) (SangStat, Lyon,
France) in 18 patients [16], or (4) FLU 30 mg/m2 days –4 to –2 and 2 Gy of
total body irradiation (TBI) in 23 patients. The dose of chemotherapy,
especially FLU, was reduced by 25–30% in patients with decreased renal
function due to nephrectomy. In addition, ATG (SangStat, Lyon, France
or Fresenius AG, Bad Homburg, Germany) was given to 25 patients and
alemtuzumab (Schering AG, Berlin, Germany) was given to two
patients due to HLA mismatch.
Prophylaxis against GVHD consisted of cyclosporine alone, cyclosporine
combined either with three or four doses of methotrexate or with
prednisolone or with mycophenolate mofetil (Table 1) [9–16, 19].
Donor lymphocyte infusions were given monthly or every second month
[16] in escalating doses to patients with progressive status, usually starting
with 1–10 · 106 CD3+ cells/kg of the recipient’s BW (n = 42). In the absence
of GVHD, this was followed by escalation of the CD3+ cell dose with 0.5–1
Volume 17 | No. 7 | July 2006
Sex (M/F)
Age, median (range), years
Donor sex (M/F)
Donor age, median (range), years
RCC type
Clear cell
Papillary
Unknown
Number of previous therapies 0/1/2/3/4
Karnofsky score pretransplant (%)
60–70/80/90–100
Status at HSCTa
Progressive disease
Stable disease
Partial remission
Recipient CMV serology (+/ÿ)
Donor CMV serology (+/ÿ)
Donor
HLA identical sibling
Mismatched related
Matched unrelated
CD34+ cell dose, median (range) (·106/kg)
Follow up, median (range), years
Conditioning
Fludarabin/Cyclophosphamide (Cy)
Fludarabin/Cy/Thiotepa
Fludarabin/TBI 2 Gy
Fludarabin/Busulphan
Fludarabin/Thiotepa
GVHD prophylaxis
Cyclosporine (CsA)
CsA/Methotrexate
CsA/Prednisolone
CsA/Mycofenolate mofetil
92/32
52 (18–68)
65/57a
47 (21–73)
111
7
6
6/52/37/20/9
20/23/81
108
9
4
77/32a
65/44a
106
5
13
5.5 (0.78–20.5)
1.3 (0.22–3.4)
53
29
23
18
1
36
62
1
25
CMV, cytomegalovirus; asome patient data is missing.
log (n = 25). Twelve patients received a third dose of 5–10 · 107 CD3+
cells/kg. Five patients received four to five DLI doses.
chimerism and graft-versus-host disease
Chimerism was analysed using the local PCR amplification method by
variable number of tandem repeats on CD3+ cells separated with
immunomagnetic beads [20]. In some centres, PCR was applied on total
DNA extracted from lymphoid peripheral blood cells after gradient
centrifugation. Complete donor chimerism (DC) was defined as ‡95% of the
separated cell populations being of donor origin. Acute GVHD was
diagnosed from clinical symptoms and/or biopsies from skin, oral mucosal
membranes, liver and gut. Acute GVHD was graded from 0 to IV, grade
0 referring to limited, grade I mild, grade II moderate, grade III-IV severe
with grade IV being life-threatening [2–4]. In limited to mild acute GVHD,
less than 50% of the body surface showed signs of reddish inflammation, and
in grade II it was more than 50%. Acute GVHD grade III consisted of more
severe skin inflammation and/or inflammatory bowel and/or liver
dysfunction. Chronic GVHD occurring after 90 days post-HSCT was
classified as limited or extensive [2–4].
doi:10.1093/annonc/mdl086 | 1135
Downloaded from http://annonc.oxfordjournals.org/ by guest on August 29, 2015
Between July 1999 and September 2003, 124 patients with metastatic RCC
underwent HSCT at 21 European centres. Patient and donor characteristics
are given in Table 1. All but six patients underwent tumour reducing
nephrectomy before HSCT. Second to fourth line therapy, often including
immunotherapy with interferon-a or interleukin-2, was given to 66 patients.
At the time of HSCT, 108 patients had progressive disease, nine had stable
disease, four partial remission and three were not reported. The locations of
the metastases were the following: lungs 85 patients, lymph nodes 48, bone
41, liver 30, brain five, other in 33 patients. The five patients with brain
metastases were included when in partial remission (n = 2), stable disease
(n = 1) or progressive disease (n = 2). Four of them had more than two sites
of metastases. In the total study group, three of the four patients with partial
remission had metastases in lungs and liver, one of them in addition had
bone metastases. A Karnofsky score pretransplant was 90–100% in 81, 80%
in 23, and 60–70% in 20 patients. Karnofsky score for the patients with brain
metastases was 70% (n = 3) and 90% (n = 2). Most donors were HLAidentical siblings (n = 106, Table 1). A few mismatched related and HLA A, B
and DR subtype antigen matched unrelated donors were used. HLA-typing
was initially serologic for class I and high-resolution polymerase chain
reaction-single-stranded polymorphism (PCR-SSP) for HLA class II. In
some centres, PCR-SSP was also used for HLA class I, especially when
selecting unrelated donors. All patients received peripheral blood stem cells
(PBSC) from donors treated with granulocyte colony-stimulating factor
(G-CSF) of 10 lg/kg/day given for 5–7 consecutive days. A median of 5.5
(range 0.78–20.5) ·106 CD34+ cells/kg of recipient’s body weight (BW)
was infused following 2 to 4 aphereses.
This study collects the data from two prospective protocols, the phase I
study of the European Group for Blood and Marrow Transplantation Solid
Tumour Working Party (EBMT STWP) and the French ITAC group on
RCC patients [16]. The protocols were approved by the respective ethics
committee at each centre and informed consent was given.
Table 1. Patient demographics of 124 haematopoietic stem cell
transplanted patients with metastatic renal cell carcinoma (RCC)
original article
metastatic responses
Complete response (CR) was defined as disappearance of all measurable
lesions. Partial response (PR) was defined as a more than 50% decrease of
the sum of all metastatic lesions for at least 30 days. A patient had a stable
disease (SD) when she/he did not qualify as partial or complete responder
or progressive disease. This required at least 1 month of duration but
usually a 3-monthly follow-up was reported. Progressive disease (PD) was
defined as increase in size of more than 25% in one or more lesions and/or
appearance of new metastases. All patients underwent computer
tomography (CT) scanning before HSCT and at least at 3, 6 and 12 months
during the first year and then at least yearly. In some centres, CT was
performed every month.
statistics
was diagnosed as limited in 21 and extensive in 18 of 98 evaluable
patients at median 122 days (range 69–485 days) after HSCT.
Transplant-related mortality (TRM), i.e. death from all causes
but cancer, occurred at a cumulative incidence of 16% (95% CI;
8.4–23.6%) including GVHD (n = 8), multi-organ failure
(n = 4), infections (n = 5) and other causes (n = 2) (Table 2).
tumour responses
A complete tumour response was seen in four of 98 evaluable
patients. Partial response was seen in 24 patients. During the
study, 24 patients had a stable disease. Sixty-seven patients had
progressive disease with a fatal outcome in 54 cases. Five
patients died early in HSCT related complications. A tumour
response was seen in 28 of 98 evaluable patients. The cumulative
incidence of response was 32% (95% CI; 18–46%) (Figure 2).
Complete response (n = 4) was seen at median 265 (range 180–
315) days after HSCT, while partial response (n = 24) was seen
median 135 (range 42–600) days. Eleven of the 45 patients
(24%) given ATG showed CR (n = 1) or PR (n = 10) and
17 of 74 patients (23%) not given this treatment presented
with CR (n = 3) or PR (n = 14) (ns).
results
engraftment, donor lymphocyte infusions and
transplant-related complications
All but three patients engrafted (98%). An absolute neutrophil
count (ANC) of more than 0.5 · 109/l for three consecutive days
was reached at a median of 12 days (range 0–28 days) after
HSCT. A platelet count of more than 20 · 109/l in the absence of
transfusions was reached on a median of 9 days (range 0–43
days) in 110 patients with available data. Complete donor CD3+
cell engraftment was seen in 32 of 96 (33%) patients at one
month, 48 of 80 (60%) at three months, and in 45 of 51 (88%)
of the patients analysed at six months post-HSCT. At 30 days
post-HSCT, patients given fludarabine, busulphan and ATG
based RIC showed the earliest DC (Figure 1).
The first DLI was given at median 124 (range 42–620) days
after SCT. The response to DLI was reported as PR (n = 9),
SD (n = 10) and PD (n = 15).
Reactivation of cytomegalovirus (CMV) was diagnosed in
33/106 (31%) of the patients. One patient developed a fatal
CMV pneumonitis (Table 2).
Acute GVHD grades II–IV developed in 47 of 119 patients at
median 55 days (range 9–196 days) after HSCT with
a cumulative incidence of 40% (95% CI; 30.2–49.8%). Acute
GVHD grades I, II, III and IV were reported in 17, 26, 13 and
eight patients, respectively. In many patients, this occurred soon
after cyclosporine withdrawal, or following DLI. Chronic GVHD
1136 | Barkholt et al.
Figure 1. Degree of donor chimerism after allogeneic haematopoietic stem
cell transplantation for metastatic renal cell carcinoma using four different
conditioning protocols. Median and 25–75% CI. Figures at the bottom
give the number of patients evaluated at each time point (*).
Table 2. Fatal outcome in toxicity of reduced intensity conditioning and
allogeneic stem cell transplantation in 124 renal cell carcinoma patients
Type of toxicity
No. of patients
Graft-versus-host disease (grade III-IV)
Infections
Fungal infection
Bacterial septicemia
Cytomegalovirus pneumonitis
Multi-organ failure
Others
Hemorrhagic cystitis
Type not reported
Total
8
5
2
2
1
4
2
1
1
19
(%)
(6.5)
(4.0)
(3.2)
(1.6)
(15.3)
Volume 17 | No. 7 | July 2006
Downloaded from http://annonc.oxfordjournals.org/ by guest on August 29, 2015
Survival was analysed on 10 February 2004 with the Kaplan-Meier product
limit method and using the log-rank (Mantel-Haenzel test), taking censored
data into account. Time to TRM, response, acute and chronic GVHD was
estimated using a non-parametric estimator of cumulative incidence curves.
Competing events for TRM were death or progressive disease, for response
death without response, and for GVHD death without GVHD. A patient
was defined as evaluable concerning tumour response and chronic GVHD
if she/he had survived more than 90 days [21, 22]. The Cox’ regression
model was used for survival and tumour response in uni- and multivariate
analysis. In the multivariate analysis, factors with P < 0.10 in the univariate
analysis were introduced into the stepwise elimination multivariate analysis.
This was done to reduce the number of competing factors in the multivariate
analysis. Risk-factors included in the analysis were: patient and donor sex
and age, previous therapies, Karnofsky score, number of metastases, CMV
status, conditioning, ATG, GVHD prophylaxis, HLA match, nucleated cell
dose, DLI, acute and chronic GVHD, number of metastatic localisations.
Analyses were performed using the cmprsk package (developed by Gray,
June 2001), Splus 6.2 software and Statistica software.
Annals of Oncology
Annals of Oncology
original article
In multivariate analyses, tumour response was associated
with a time period of less than one year from the diagnosis
of RCC to HSCT, HLA mismatched donor and acute GVHD
II-IV (Table 3). The various RIC protocols, the different
immunosuppressive regimens used and donor CD3+ cell
engraftment had no significant impact on tumour response
or survival. Localisation or number of the metastatic sites did
not influence the response, neither of the patients had SD or PD
pre-HSCT. The four patients with complete response had the
following common features: few metastatic localisations, a high
Karnofsky score, shorter time to reach a full donor chimerism,
and three of them developed chronic GVHD before response.
discussion
A report by Childs and co-workers with a tumour response rate
of 10 of 19 in patients undergoing HSCT for RCC encouraged
the present European trials [9]. In addition, the trials were
justified due to the extremely poor prognosis in metastatic RCC
with a median survival usually of less than 1 year [23, 24].
Systemic chemotherapy is ineffective, but some responses have
been seen with interleukin-2 and interferon-a, with response
rates below 20% [22–26].
A recent study showed that neutralising antibody against
vascular endothelial growth factor (VEGF) prolonged the time
Volume 17 | No. 7 | July 2006
Figure 2. Cumulative incidence of patients with tumour response after
allogeneic haematopoietic stem cell transplantation for metastatic renal
cell carcinoma. A patient was defined as evaluable concerning tumour
response if she/he survived more than three months. Time to and
cumulative incidence of transplant-related mortality (TRM) and time to
and cumulative incidence of death by progressive disease are given.
Figure 3. Cumulative proportion of surviving patients undergoing
allogeneic haematopoietic stem cell transplantation for metastatic renal
carcinoma with a Karnofsky score of 90–100%, 80% or 60–70% (P < 0.001
between the two first groups and the third one). Tic marks represent
surviving patients. Survival is counted from day of transplantation.
to progression of disease in patients with RCC, although
survival was not significantly prolonged [27]. Furthermore, the
first full report of a multitargeted tyrosine kinase inhibitor
(TKI) of VEGF and platelet-derived growth factor receptors as
a second-line treatment for patients of metastatic RCC
demonstrated partial responses in 40% of patients with
a median survival of 16.4 months [28]. These results are under
evaluation in the light with preliminary reports on other TKIs
[29]. The present European multicentre study confirms the
previous encouraging effects using HSCT for patients with
metastatic RCC [9, 12–16, 30].
Because of the TRM associated with HSCT, this procedure is
in general only performed in patients with an otherwise dismal
doi:10.1093/annonc/mdl086 | 1137
Downloaded from http://annonc.oxfordjournals.org/ by guest on August 29, 2015
survival
Overall patient survival was 30% at two years after HSCT. Sixtythree patients died of progressive disease. All five patients with
brain metastases died of progressive disease median 5 (range
1–21) months after SCT. Among the four patients undergoing
HSCT while in partial remission, two died of progressive
disease. When chronic GVHD was included in the multivariate
analysis of survival, a landmark analysis on patients surviving
more than 90 days post HSCT was performed. In univariate
analysis, poor survival was associated with the following factors:
a Karnofsky score <80% (P < 0.001), lymph node metastases
(P = 0.016), liver metastases (P = 0.08), bone metastases
(P = 0.02), no DLI (P < 0.001), no chronic GVHD (P < 0.001) or
number of metastases (‡3, P < 0.001). Patients with a Karnofsky
score of >70% had a better survival, compared to those between
60 and 70% (Figure 3, P < 0.001). Patients with two or fewer
sites of metastases (n = 88) had a better survival, compared to
those with 3–5 locations of metastases (n = 35) (Figure 4,
P < 0.001). Patients with chronic GVHD who also received DLI
(n = 17) had a 2-year survival of 70% (Figure 5). In contrast,
patients without chronic GVHD and not given DLI (n = 34) had
a 2-year survival of 18% (P < 0.001). Patients with chronic
GVHD and not given DLI (n = 22) or patients given DLI
without development of chronic GVHD (n = 24) showed in
both groups a similar survival between these two extremes. The
probability of survival was significantly better for patients given
DLI compared to patients not given DLI, 62% versus 39% at
1 year (P = 0.003; a landmark analysis from day 90). In
multivariate analysis of overall patient survival, chronic GVHD,
DLI, a Karnofsky score ‡80% and less than three sites of
metastases, were associated with improved survival after HSCT
(Table 3).
original article
Annals of Oncology
Table 3. Results from multivariate analysis for tumour response and
survival among 124 haematopoietic stem cell transplanted patients
with renal cell carcinoma
Response (CR + PR)
OR
Time diagnose-HSCT
Mismatched donor
Acute GVHD II-IV
95% CI
P-value
1.29–6.71
1.55–31.3
1.13–5.19
0.009
0.01
0.02
‡1y/<1y
No/Yes
No/Yes
2.94
6.96
2.43
HR
95% CI
P-value
No/Yes
No/Yes
3–5/0–2
60–70/80–100
4.12
3.39
2.61
2.33
2.20–7.69
1.86–6.18
1.44–4.74
1.09–4.97
<0.001
<0.001
0.002
0.03
Survival
Chronic GvHD
DLI
No. of metastatic sites
Karnofsky score (%)
Figure 5. Cumulative proportion of surviving patients undergoing
allogeneic haematopoietic stem cell transplantation for metastatic renal
cell carcinoma with or without chronic graft-versus-host disease
(cGVHD), and given donor lymphocyte infusions (DLI). P < 0.001 for the
patients with chronic GHVD and given DLI as compared to those without
chronic GVHD and not given DLI. Only patients surviving at least 90 days
are included. Tic marks represent surviving patients.
outcome. To reduce TRM, reduced intensity conditionings have
been introduced to treat haematological malignancy patients
of high age or with organ impairment who would not be
considered for full myeloablative chemoradiotherapy and HSCT
[17–19]. Lately, RIC has also been used for metastatic solid
tumours non-responsive to chemoradiotherapy [9–16]. In the
present study, the cumulative probability of TRM was 16%,
which may be improved with a better patient selection. Patients
offered RIC and allogeneic HSCT should manage the treatment
related potential toxicity of GVHD and infections counted
into TRM. Although the maturation of the new immunity even
after RIC may take over one year, in this study, infectious
complications were rare (4%, Table 2).
1138 | Barkholt et al.
CR, complete response; PR, partial response; OR, odds ratio;
CI, confidence interval; HR, hazards ratio; DLI, donor lymphocyte
infusion.
Using RIC, there may be an increased risk of graft failure,
compared to full myeloablative chemoradiotherapy. Graft
failure rates of up to 20% have been reported using RIC by
McSweeney et al. [31]. A graft failure rate of only 3% in the
present series is therefore encouraging. However, McSweeney
and co-workers only used 2 Gy of TBI as conditioning,
combined with cyclosporine and mycophenolate mofetil as the
post-transplant immunosuppression. This regimen has been
reported to be associated with an increased risk of graft failure
and also GVHD due to relatively long-lasting mixed chimerism
allowing antigen presenting cells and T-cells of recipient origin
to interfere as compared to the conditioning regimens used in
most patients in the present study [32]. We found no significant
effect of different RIC protocols or GVHD prophylaxis used
regarding tumour response or survival. The use of ATG did not
influence tumour response. Interestingly, time to complete
donor chimerism seemed faster using fludarabine, busulphan
and ATG compared to the other RIC protocols (Figure 1). The
role of ATG in this context needs to be evaluated. A correlation
between donor chimerism and tumour response was earlier
reported [9]. Therefore, more patients are needed to evaluate
the optimal RIC protocol.
A complete and partial response rate of 29% of patients is
similar to that seen by Artz et al. [12], but lower than 54%
reported by Childs and colleagues [9]. This difference may be
due to patient selection with more patients with advanced
disease in the present report. Tumour response was associated
with a short time from diagnosis to HSCT, HLA mismatched
donors and GVHD (Table 3). Early transplantation seems
beneficial, before the metastases are too widespread. In
multivariate analysis, number of localisations of metastases,
rather than the type of metastases, and a low Karnofsky
score were significant factors also for survival. Furthermore,
a previous study on HSCT for RCC showed that low
performance status, increased CRP and LD were correlated
to a poor prognosis [33].
The importance of HLA mismatch suggests an allogeneic
anti-tumour effect directed against HLA antigens on the surface
of the metastatic cells. This effect is further strengthened by the
Volume 17 | No. 7 | July 2006
Downloaded from http://annonc.oxfordjournals.org/ by guest on August 29, 2015
Figure 4. Cumulative proportion of surviving patients undergoing
allogeneic haematopoietic stem cell transplantation for metastatic renal
carcinoma with two or fewer locations with metastases, compared to three
or more (P < 0.001). Tic marks represent surviving patients.
original article
Annals of Oncology
Volume 17 | No. 7 | July 2006
patients at an earlier stage with a low tumour burden. It is
probable that metastatic RCC requires several therapeutic
strategies to significantly improve the long-term survival. It may
be necessary to combine HSCT with other therapies, such as
irradiation against metastases, anti-VEGF antibodies, TKIs,
interferon-a, interleukin-2, etc. in order to prevent the risk for
tumour escape mechanisms [38]. Combining the more direct
tumour necrotising and inflammatory effect of the latter with
the slowly developing allogeneic antitumour effect of HSCT
using less toxic RIC offers a new platform in cancer therapy.
Results on allogeneic HSCT in metastatic RCC may warrant
further studies on patients with other metastatic solid tumours.
Indeed, such studies are under way in the USA and within the
EBMT.
To conclude, we observed tumour responses in a fraction of
patients with metastatic RCC receiving allograft as salvage
therapy. Based on the findings of this trial, patients with less
than three metastatic sites and a Karnofsky score >70% can be
considered for HSCT. Furthermore, it seems important to
include DLI in the protocol and try to induce limited
chronic GVHD.
acknowledgements
We thank the staff at the various transplant centres for
compassionate and competent patient care. We thank Inger
Hammarberg for typing the manuscript. We also thank
our colleagues Dr P.E. Alessandrino (IRCCS Policlinico
San Matteo, Pavia, Italy), Dr A. Bosi (Ospedale di Careggi,
Firenze, Italy), Dr L. Castagna (Instituto Clinico Humanitas,
Milan, Italy), Dr P. Corradini (Instituto Nazionale Tumouri,
Milan, Italy), Dr L. Gugliotta (Unita Operativa Ematologia,
Reggio Emilia, Italy), Dr J.M. Moraleda (Hospital Morales
Meseguer, Murcia, Spain), Dr M. Musso (Ospedale La
Maddalena, Palermo, Italy) and Dr J. Roigas (Hospital Charité,
Berlin, Germany) for reporting patients to this study. This study
was supported by grants from The Swedish Cancer Society,
The Swedish Children’s Cancer Society, The Swedish Research
Council, The Cancer Society in Stockholm and the Karolinska
Institutet, Stockholm, Sweden. In addition, Dr M. Bregni,
Dr J. Peccatori, Dr P. Pedrazzoli and Dr S. Siena were partly
supported by a grant from the Associazione Italiana per la
Ricerca sul Cancro.
references
1. Truitt RL, Shih C-Y, LeFever AV. Manipulation of graft-versus-host disease for
a graft-versus-leukemia effect after allogeneic bone marrow transplantation in
AKR mice with spontaneous leukaemia/lymphoma. Transplantation 1986; 41:
301–310.
2. Weiden PL, Fluornoy N, Thomas ED et al. Anti-leukemic effect of graft-versushost disease in human recipients of allogeneic marrow grafts. N Engl J Med
1979; 300: 1068–1073.
3. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after
bone marrow transplantation. Blood 1990; 75: 555–562.
4. Ringdén O, Labopin M, Gluckman E et al. Graft-versus-leukemia effect in
allogeneic marrow recipients with acute leukaemia is maintained using
cyclosporine A combined with methotrexate as prophylaxis. Bone Marrow
Transplant 1996; 18: 921–929.
doi:10.1093/annonc/mdl086 | 1139
Downloaded from http://annonc.oxfordjournals.org/ by guest on August 29, 2015
correlation between grades II–IV acute GVHD and response,
which also confirms previous studies on allogeneic HSCT
against solid tumors [9, 12, 14]. Harlin et al. demonstrated that
the clinical tumour response in RCC patients after HSCT was
associated with an expansion of interferon-a producing CD8+
T-cells [34]. Similarly, in patients treated using RIC and
allogeneic HSCT for colorectal cancer, carcino-embryonal
antigen (CEA) specific T-cells were detected concomitantly
with GVHD and were associated with a decrease of serum
CEA levels as well as clinical partial remission [35].
For survival, chronic GVHD and DLI were of utmost
significance (Figure 5, Table 3). In patients with leukaemia,
chronic GVHD has been found to have a more profound
antileukaemic effect, compared to acute GVHD [2–4].
Obviously, chronic GVHD has an important effect on survival
in metastatic RCC. This has not been reported previously. In
the study of Childs and colleagues, the observation time was
shorter and only four patients developed chronic GVHD. In that
study, eight patients received up to three escalating doses of
DLI with no effect on tumour responses or survival. In this
European multicentre study, patients with chronic GVHD and
receiving DLI had a survival of 70% two years after transplant
(Figure 5, Table 3). Six patients got DLI after they had developed
chronic GVHD. Based on these findings, patients with metastatic
RCC should probably discontinue their immunosuppression
early in the absence of GVHD to induce chronic GVHD. Indeed,
in HLA-identical sibling transplants for leukaemia, those with
low-dose cyclosporine of short duration had an increased
probability of mild acute and chronic GVHD, resulting in
a reduced probability of leukaemic relapse [36]. Such an
approach may also be used in patients with metastatic RCC,
because Childs and colleagues reported a correlation between
acute GVHD and tumour response and the present study showed
an anti-tumour effect of chronic GVHD [9]. In addition to
chronic GVHD, RCC patients seem to need DLI. However, we
still need to improve interventions of severe GVHD to decrease
the TRM since severe GVHD is after relapse the second most
common reason for fatal outcome in allogeneic HSCT.
At present, it is not possible to compare the outcome in HSCT
patients with that using conventional therapy, or using
interleukin-2, interferon-a, new inhibitors of the VEGF receptor
or their combinations [23–29]. Using earlier cytokine-based
immunotherapies, 3-year survival is reported around 20%
[23–26]. Results of the first single-agent antibody against VEGF,
bevacizumab, have improved in a trial combining it with
another antibody, erlotinib, giving a median survival time of
23 months [27, 37]. In phase I/II trials for metastatic RCC, single
agent antibodies against VEGF and TKIs have shown partial
responses or stable disease and minor responses in
approximately 20–50% and 40–80% of patients, respectively
[29]. These impressive results are to be regarded as a step
towards a reality of life-prolonging therapies with manageable
but still treatment-limiting toxicity in elder patients. However, it
is presently unknown if the patients with partial and complete
responses with any therapy will be cured or not due to tendency
of the development of tumor resistance. Longer observation
times and additional studies on the precise clinical mechanisms
of these drugs are required. As is the case in patients with
leukaemia undergoing HSCT, it may be important to select
original article
1140 | Barkholt et al.
22. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and
presentation of the results of bone marrow transplants. Part 2: Regression
modeling. Bone Marrow Transplant 2001; 28: 1001–1011.
23. Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with
stage IV renal cell carcinoma. Clin Cancer Res 2004; 10: 6302S-3S.
24. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell
carcinoma: 1983–1993. Semin Oncol 1995; 22: 42–60.
25. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive
patients with metastatic melanoma or renal cell cancer using high-dose bolus
interleukin 2. JAMA 1994; 271: 907–913.
26. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2,
recombinant human interferon alfa-2a, or both in metastatic renal cell
carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med 1998; 338:
1272–1278.
27. Yang JC, Haworth L, Sherry RM et al. A randomised trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J
Med 2003; 349: 427–434.
28. Motzer R, Michaelson MD, Reman BG et al. SU11248, a multi-targeted inhibitor
of vascular endothelial growth factor receptor and platelet-derived growth factor
receptor, demonstrated antitumor activity in patients with metastatic renal cell
carcinoma. J Clin Oncol 2006; 24: 16–24.
29. Vogelzang NJ. Treatment options in metastatic renal carcinoma: an embrassment
of riches. J Clin Oncol 2006; 24: 1–3.
30. Gommersall L, Hayne D, Lynch C et al. Allogeneic stem-cell transplantation for
renal-cell cancer. Lancet Oncol 2004; 5: 561–567.
31. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell
transplantation in older patients with hematologic malignancies: replacing
high-dose cytotoxic therapy with graft-versus-tumour effects. Blood 2001; 97:
3390–3400.
32. Le Blanc K, Remberger M, Uzunel M et al. A comparison of non-myeloablative
versus reduced intensity conditioning for allogeneic stem cell transplantation.
Transplantation 2004; 78: 1014–1020.
33. Peccatori J, Barkholt L, Demirer T et al. Prognostic factors for survival in patients
with advanced renal cell cancer undergoing non-myeloablative allogeneic stem
cell transplantation. Cancer 2005; 10: 2099–2103.
34. Harlin H, Artz AS, Mahowald M et al. Clinical responses following
nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are
associated with expansion of CD8+ IFN-y-producing T cells. Bone Marrow
Transplant 2004; 33: 491–497.
35. Carnevale-Schianca F, Cignetti A, Capaldi A et al. Allogeneic nonmyeloablative
hematopoietic cell transplantation in metastatic colon cancer: tumor-specific
T-cells directed to a tumor-associated antigen are generated in vivo during
GVHD. Blood Jan 2006; doi:10.1182/blood-2005-10-3945.
36. Carlens S, Aschan J, Remberger M et al. Low-dose cyclosporine of short duration
increases the risk of mild and moderate GVHD and reduces the risk of relapse in
HLA-identical sibling marrow transplant recipients with leukemia. Bone Marrow
Transplant 1999; 24: 629–635.
37. Spigel DR, Hainsworth JD, Sosman JA et al. Bevacizumab and erlotinib in
the treatment of patients with metastatic renal carcinoma (RCC): Update
of a phase II multicenter tiral. J Clin Oncol 2005; 23 (Suppl): 387 (Abstr.
4540).
38. Rini BI, Sosman JA, Motzer RJ. Therapy targeted at vascular endothelial growth
factor in metastatic renal cell carcinoma: biology, clinical results and future
development. B J Urol International 2005; 96: 286–290.
Volume 17 | No. 7 | July 2006
Downloaded from http://annonc.oxfordjournals.org/ by guest on August 29, 2015
5. Kolb H-J, Schattenberg A, Goldman J et al. Graft-versus-leukemia effect of
donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86:
2041–2050.
6. Eibl B, Schwaighhofer H, Nachbaur D et al. Evidence of graft-versus-tumour
effect in a patient treated with marrow ablative chemotherapy and
allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88:
1501–1508.
7. Ben-Yosef R, Or R, Nagler A et al. Graft-versus-tumour and graft-versusleukaemia effect in patients with concurrent breast cancer and acute myeloid
leukaemia. Lancet 1996; 348: 1242–1243.
8. Ueno NT, Rondón G, Mirza NQ et al. Allogeneic peripheral-blood progenitor-cell
transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol
1998; 16: 986–993.
9. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell
carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell
transplantation. N Engl J Med 2000; 343: 750–758.
10. Zetterquist H, Hentschke P, Thörne A et al. A graft-versus-colonic cancer effect
after allogeneic stem-cell transplantation. Bone Marrow Transplant 2001; 28:
1161–1166.
11. Bay JO, Fleury J, Choufi B et al. Allogeneic hematopoietic stem cell
transplantation in ovarian carcinoma: results of five patients. Bone Marrow
Transplant 2002; 30: 95–102.
12. Artz AS, van Besien K, Zimmerman T et al. Long-term follow-up of
nonmyeloablative allogeneic stem cell transplantation for renal cell
carcinoma: The University of Chicago Experience. Bone Marrow Transplant
2005; 35: 253–260.
13. Gratwohl A, Baldomero H, Demirer T, Rosti G, Dini G, Ladenstein R, UrbanoIspizua A. Hematopoetic stem cell transplantation for solid tumors in Europé.
Ann Oncol 2004; 15: 653–660.
14. Bregni M, Dodero A, Peccatori J et al. Nonmyeloablative conditioning followed
by hematopoietic cell allografting and donor lymphocyte infusions for patients
with metastatic renal and breast cancer. Blood 2002; 99: 4234–4236.
15. Hentschke P, Barkholt L, Uzunel M et al. Low-intensity conditioning and
hematopoietic stem cell transplantation in patients with renal and colon
carcinoma. Bone Marrow Transplant 2003; 31: 253–261.
16. Blaise D, Bay JO, Faucher C et al. Reduced-intensity preparative regimen and
allogeneic stem cell transplantation for advanced solid tumours. Blood 2004;
103: 435–441.
17. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic
progenitor cells with purine analog-containing chemotherapy: Harnessing
graft-versus-leukemia without myeloablative therapy. Blood 1997; 89:
4531–4536.
18. Slavin S, Nagler A, Naparstek E et al. Non myeloablative stem cell transplantation
and cell therapy as an alternative to conventional bone marrow transplantation
with lethal cytoreduction for the treatment of malignant and non-malignant
hematologic diseases. Blood 1998; 91: 756–763.
19. McSweeney P, Storb R. Mixed chimerism: preclinical studies and clinical
applications. Biol Blood Marrow Transplant 1999; 5: 192–203.
20. Mattsson J, Uzunel M, Remberger M et al. Minimal residual disease is
common after allogeneic stem cell transplantation in patients with B-cell
chronic lymphocytic leukemia and may be controlled by graft-vs-host disease.
Leukemia 2000; 14: 247–254.
21. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and
presentation of the results of bone marrow transplants. Part I: unadjusted
analysis. Bone Marrow Transplant 2001; 28: 909–915.
Annals of Oncology